ADP-0055-001-MAGE-A4-SURPASS
Phase I
OPEN TO ACCRUAL
A Phase 1 Dose Escalation Study to Assess Safety and Efficacy Of ADP-A2m4cd8 As Monotherapy or in Combination with Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
IIT-GORE-REDIRICT
Phase II
OPEN TO ACCRUAL
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
- Anus
- Brain and Nervous System
- Breast
- Cervix
- Colon
- Esophagus
- Kidney
- Larynx
- Lip, Oral Cavity and Pharynx
- Liver
- Lung
- Other Digestive Organ
- Other Endocrine System
- Other Female Genital
- Other Male Genital
- Other Respiratory and Intrathoracic Organs
- Other Urinary
- Ovary
- Pancreas
- Prostate
- Rectum
- Small Intestine
- Soft Tissue
- Stomach
- Thyroid
- Unknown Sites
- Urinary Bladder
IIT-HALL-MRI-ENHANCE
Phase I/II
OPEN TO ACCRUAL
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer